# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Eli Lilly reports detailed results from the SYNERGY-NASH phase 2 study. The trial, involving 190 patients with and without type...
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously pub...
Jefferies analyst Akash Tewari maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $925 to $957.
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest.
May labor market report: strong job gains and wage growth, reduces chances of rate cut. Interest-rate sensitive sectors underpe...
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and t...
Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shift...
The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10....